相关实验视频
Updated: May 15, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
心血管实践中的人工智能
Marci Farquhar-Snow1, Amy E Simone, Sheel V Singh
1Marci Farquhar-Snow is a retired assistant professor, formerly practicing in the Department of Cardiovascular Medicine at Mayo Clinic College of Medicine and Science in Scottsdale, Ariz. Amy E. Simone is a consultant at Edwards Lifesciences in Burlingame, Calif. Sheel V. Singh is a second-year student in the PhD program in Health and Rehabilitation Sciences at Massachusetts General Hospital Institute of Health Professions in Boston, Mass. Reamer L. Bushardt is provost and vice president for academic affairs and a professor at Massachusetts General Hospital Institute of Health Professions, as well as a research associate in the Department of Physical Medicine and Rehabilitation at Harvard Medical School in Boston, Mass. Marci Farquhar-Snow serves on the Cardiovascular Team Editorial Board at the Journal of the American College of Cardiology . Amy E. Simone is chair-elect, CV Team Section Leadership Council, American College of Cardiology, and founder of JC Medical. Reamer L. Bushardt is editor-in-chief emeritus of JAAPA . The authors have disclosed no other potential conflicts of interest, financial or otherwise.
人工智能 (AI) 正通过引入新的模型和应用来改变心血管保健. 临床医生在这些先进的人工智能技术的伦理发展和采用方面发挥着至关重要的作用.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 人工智能的人工智能
背景情况:
- 人工智能 (AI) 在各个领域越来越普遍.
- 它在心血管保健中的应用正在迅速扩大,需要对其使用有明确的理解.
研究的目的:
- 探索用于心血管护理的常见人工智能 (AI) 模型.
- 检查人工智能如何改变心脏病学领域的医疗保健.
- 定义临床医生在AI的开发,采用,评估和道德实施中的角色.
主要方法:
- 对心血管医学当前的人工智能 (AI) 模型的审查.
- 分析AI对医疗保健提供流程的影响.
- 讨论AI整合中的临床责任.
主要成果:
- 确定了适用于心血管疾病的常见AI模型.
- 证明了AI在提高诊断准确性和治疗个性化方面的潜力.
- 强调临床医生参与人工智能治理的关键需要.
结论:
- 人工智能 (AI) 为推进心血管保健提供了巨大的潜力.
- 临床医生,包括先进实践提供者,对于人工智能的负责任和有效整合至关重要.
- 伦理考虑和严格的评估对于成功地在心脏病学中采用人工智能至关重要.
更多相关视频
相关概念视频
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Pre-Procedural Guidelines for Assessing Blood Pressure
Cardiovascular Drugs: Classification based on Therapeutic Indications

